Table 2. Univariate analysis of patient and tumour in relationship to active caspase 3 expression in tumour and tumour-associated stroma.
| χ2 test (P value) | ||||||
|---|---|---|---|---|---|---|
| |
CC3 expression | Cleaved PARP | MHC-II expression | |||
| Variable | Tumour | Tumour-associated stroma | Tumour | Tumour-associated stroma | Tumour | Tumour-associated stroma |
| Gender |
0.832 |
0.579 |
0.427 |
0.524 |
0.116 |
0.656 |
| Tumour site |
0.729 |
0.364 |
0.884 |
0.410 |
0.757 |
0.058 |
| Tumour grade |
0.196 |
0.266 |
1.000 |
0.255 |
0.036 |
0.190 |
| Duke's stage |
0.026 |
0.298 |
0.288 |
0.844 |
0.157 |
0.706 |
| TNM stage |
0.047 |
0.462 |
>0.001 |
>0.001 |
0.007 |
0.969 |
| Distant metastases |
0.005 |
0.188 |
1.000 |
0.005 |
0.237 |
0.989 |
| Extramural vascular invasion |
0.775 |
0.368 |
0.392 |
0.604 |
0.249 |
0.049 |
| Stromal MHC-II expression |
0.151 |
0.020 |
0.005 |
0.011 |
— |
— |
| Tumoural MHC-II expression |
0.008 |
0.347 |
0.959 |
1.000 |
— |
— |
| CD3—intratumoural |
0.557 |
0.525 |
0.525 |
0.297 |
0.002 |
0.002 |
| CD3—tumour-associated stroma |
0.821 |
0.569 |
0.569 |
0.651 |
0.001 |
0.001 |
| CD16 |
0.762 |
0.490 |
0.490 |
0.522 |
0.002 |
0.004 |
| CD68 |
0.631 |
0.313 |
0.313 |
1.000 |
0.865 |
<0.001 |
| p53 |
0.616 |
0.919 |
0.919 |
0.379 |
0.069 |
0.394 |
| Bcl-2 |
0.681 |
0.290 |
0.290 |
0.486 |
0.362 |
0.145 |
| CC3 tumour |
— |
0.221 |
>0.001 |
>0.001 |
— |
— |
| CC3 tumour-associated stroma |
0.221 |
— |
0.218 |
>0.001 |
— |
— |
| Cleaved PARP tumour |
— |
— |
— |
>0.001 |
— |
— |
| Cleaved PARP tumour-associated stroma | — | — | >0.001 | — | — | — |
Abbreviations: CC3=cleaved caspase-3; MHC-II=major histocompatibility class II; PARP=poly (ADP-ribose) polymerase; TNM=Tumor, Node, Metastasis. P values <0.05 are indicated in bold.